A randomized, placebo controlled trial of an antisense oligodeoxynucleotide to intercellular adhesion molecule-1 in the treatment of severe rheumatoid arthritis

Journal of Rheumatology

Volumn 29, Issue 3, 2002, Pages 447-453

  Maksymowych, Walter P ^a   Blackburn Jr , Warren D ^a   Tami, Joseph A ^a   Shanahan Jr , William R ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Antisense deoxynucleotide; Clinical trial; Rheumatoid arthritis

Indexed keywords

ALICAFORSEN; ANTIRHEUMATIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; COMPLEMENT COMPONENT C3A; CORTICOSTEROID; IMMUNOGLOBULIN; INTERCELLULAR ADHESION MOLECULE 1; PLACEBO;

ABDOMINAL PAIN; ADULT; AGED; ANTIGEN DETECTION; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DISEASE SEVERITY; DOSE CALCULATION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOPHENOTYPING; IMMUNOTHERAPY; MALE; MULTICENTER STUDY; NAUSEA; PARTIAL THROMBOPLASTIN TIME; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECALL; RHEUMATOID ARTHRITIS; SKIN TEST; SWEATING; SYNCOPE; TREATMENT OUTCOME; VERTIGO;

EID: 0036198566     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Induction by IL-1 and interferon gamma: Tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1)
2. A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1
3. Adhesion molecules in rheumatoid arthritis
4. Purified intercellular adhesion molecule-1 is a ligand for lymphocyte function associated antigen-1
5. ICAM-1 (CD54): A counter-receptor for Mac-1 (CD11b/CD18)
6. Leukocyte-endothelial cell recognition: Three (or more) steps to specificity and diversity
7. Monoclonal antibodies to leukocyte integrins CD11a/CD18 and CD11b/CD18 or intercellular adhesion molecule-1 inhibit chemoattractant-stimulated neutrophil transendothelial migration in vitro
8. Differential utilization of ICAM-1 and VCAM-1 during the adhesion and transendothelial migration of human T lymphocytes
9. Cotransfection of ICAM-I and HLA-DR reconstitutes human antigen-presenting cell function in mouse L cells
10. Adhesion molecules and their role in inflammation
11. Neutrophil induced oxidative injury of cardiac myocytes
12. Differential costimulatory effects of adhesion molecules B7, ICAM-1, LFA-3 and VCAM-1 on resting and antigen-primed CD4+ T lymphocytes
13. CD54/Intercellular adhesion molecule 1 and major histocompatibility complex II signalling induces B cells to express interleukin 2 receptors and complement help provided through CD40 ligation
14. The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells
15. The immunological synapse: A molecular machine controlling T cell activation
16. Inhibition of endothelial cell-leukocyte adhesion molecule expression with antisense oligonucleotides
17. Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms
18. Oligonucleotide stability in subcellular extracts and culture media
19. Regulation of endothelial cell adhesion molecule expression with antisense oligonucleotides
20. Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligonucleotide (ISIS 2302)
21. Antisense oligonucleotide inhibitors for the treatment of cancer: 11. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides
22. Pharmacokinetics and metabolism of a phosphorothioate oligonucleotide antisense inhibitor of c-RAF-1 kinase expression
23. Progress in antisense oligonucleotide therapeutics
24. Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: Potential mechanism of action
25. Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in cynomolgus monkeys
26. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
27. Analysis of improvement in individual RA patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo
28. Quantitation of phosphorothioate oligonucleotides in human plasma
29. Increased levels of circulating intercellular adhesion molecule 1 in the sera of patients with rheumatoid arthritis
30. Use of a chimeric monoclonal anti-CD4 antibody in patients with refractory rheumatoid arthritis
31. Double-blinded, randomized, placebo-controlled trial of the remission inducing and steroid sparing properties of two schedules of ISIS 2302 (ICAM-1 antisense) in active, steroid-dependent Crohn's disease
32. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease
33. Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex